Searched for
SUN PHARMA Q3 SALES
India's manufacturing growth slows in Q1 as West Asia conflict weighs: FICCIIndia's manufacturing sector anticipates a slower growth phase in the April-June quarter of FY27, influenced by the West Asia conflict. Whi...- Maruti Suzuki shares jump 5% after Jefferies upgrades rating to Buy. Here's the latest target priceMaruti Suzuki shares rose nearly 5% after Jefferies upgraded the stock to ‘Buy’ and raised its target price to Rs 16,500, citing strong pas...
- Sensex rises over 200 points, Nifty above 24,000; Maruti Suzuki shares jump 3%Indian stock markets rebounded on Tuesday, with both Sensex and Nifty climbing approximately 0.4% after a dip in the previous session. The ...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities ended lower, snapping a two-day rally as escalating Iran-US tensions and profit booking weighed on sentiment. Sensex fell 3...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East ...
- Housing sales fall 6% across top 7 cities in Q2 as West Asia conflict dents buyer sentiment; launches rise 7%: ANAROCKPersistent Systems' shares plunged nearly 11% following its announcement to acquire Germany-based Nagarro for €1.27 billion. While the deal...
- Residential sales dip to lowest since Jan 2023 amid West Asia war, impacting buyer sentimentResidential sales in India experienced a significant dip in April-June, reaching the lowest point since early 2023. Geopolitical tensions a...
- Over 10% of luxury home sales now come from NRIs across key global markets: Whiteland's Sudeep BhattIndia's luxury housing market is experiencing a structural transformation, attracting significant global capital, particularly from Non-Res...
- Will Sensex, Nifty extend gains or turn volatile? Q1 updates, F&O expiry among 8 factors set to steer stock market this weekIndian markets head into a crucial week with investors tracking Q1 business updates, June F&O expiry, auto sales data, FII flows, crude oil...
- Strides Pharma sells majority stake in arm Pivot Path for Rs 100 croreStrides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...
- Q1 earnings preview: Here’s what Nomura expects from Nestle, Titan, other consumer majors’ June quarter resultsNomura expects consumer staples to deliver a strong start to FY27, forecasting double-digit sales growth for several companies in the June ...
- Goldman Sachs upgrades India's growth outlook after US-Iran peace dealGoldman Sachs has raised India's 2026 real GDP growth forecast to 6.8% from 6.5%, citing lower oil prices, easing supply disruptions and re...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Alera Group data breach settlement: Americans could get up to $3,500 in settlement payouts-know who’s eligible and the claim deadlineA significant data breach settlement from Alera Group Inc. offers thousands of Americans a chance for compensation, with a filing deadline ...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Central Drugs Laboratories find 46 drug samples not of standard quality for MayHealth officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
Load More
